Zongertinib tablets: 60 mg/tablet, 60 tablets/box.

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Hepatotoxicity: Hepatic function tests including ALT, AST and total bilirubin should be monitored prior to dosing, every 2 weeks for 12 weeks prior to dosing, monthly thereafter as clinically indicated, and more frequently in case of transaminase elevation. Depending on the severity, LuciZonger should be interrupted, dose reduced, or permanently discontinued.
• Left ventricular dysfunction: The left ventricular ejection fraction (LVEF) is assessed before starting treatment and monitored regularly during treatment and as clinically indicated. Depending on the severity, LuciZonger should be interrupted, dose reduced, or permanently discontinued.
• Interstitial lung disease/pneumonia: Surveillance suggests new or worsening symptoms of ILD/pneumonia (e.g. dyspnea, cough, fever). Depending on the severity, LuciZonger should be interrupted, dose reduced, or permanently discontinued.
• Embryo-fetal toxicity: May cause damage to the fetus. Inform the patient of the potential risks to the fetus and take effective contraceptive measures.

Medication risks

Adverse Reactions
The most common adverse reactions (≥ 20%) were diarrhea, hepatotoxicity, rash, fatigue, and nausea. The most common (≥ 2%) grade 3 or 4 laboratory abnormalities are lymphopenia, elevated alanine aminotransferase, elevated aspartate aminotransferase, decreased blood potassium, and elevated gamma-glutamyl transferase.

【Drug interactions】
• Potent CYP3A inducers: Avoid concomitant use with potent CYP3A inducers. If simultaneous use cannot be avoided, increase the dose of LuciZonger.
• BCRP Substrates: Avoid concomitant use with certain BCRP substrates, as even a slight increase in concentration can lead to serious adverse reactions, and consider other therapies. If simultaneous use cannot be avoided, closely monitor the patient for adverse reactions and follow the recommendations in the BCRP Substrate Approval Product Specification. For other BCRP substrates, monitor for increased adverse reactions and adjust the doses of these substrates as clinically appropriate.